ClinicalTrials.gg
RecruitingNCT05713435LASIUpdated Jul 1, 2024

Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of GSM in Patients Using Aromatase Inhibitors

An interventional study of intravaginal laser in Genitourinary Syndrome of Menopause, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven — 7 open to participants now, 8 under way, 1 of them phase 3. Breast Neoplasms · Universitaire Ziekenhuizen KU Leuven.

Planned enrollment
6th of 21
162 · median 100
Started
2022
the only one that year
No phase
13 of 31
4 open now
Registered
27th of 31
by date

Among the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven, this one is the 6th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2022, is one of 13 with no phase, and was the 27th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 100 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven, or all of them as a file.
02

Study summary

To study the efficacy and safety of intravaginal CO2 laser versus intravaginal Er:YAG laser and sham application in alleviating genitourinary symptoms in patients receiving an aromatase inhibitor as adjuvant treatment of breast cancer

Read the detailed description

The objective is to compare microablative fractional CO2 laser (CO2 laser) (SmartXide2 V2 LR, Monalisa Touch; DEKA, Florence, Italy) and non-ablative photothermal Erbium:YAG laser (Er:YAG laser) (Fotona Smooth™ XS; Fotona, Ljubljana, Slovenia) - with sham vaginal applications for treatment of vaginal dryness as the leading symptom in breast cancer patients with iatrogenic menopause and treated with an AI.

03

Conditions studied

  • Genitourinary Syndrome of Menopause

Browse trials for

Keywords

  • genitourinary syndrome of menopause
  • intravaginal laser
  • breast cancer
  • aromatase inhibitor
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Recruited participants will meet all of these criteria:

  • a history of breast cancer
  • premenopausal at diagnosis of breast cancer
  • using AI as an treatment
  • moderate to severe symptoms of GSM (VAS ≥ 4/10)
  • currently menopausal, which can be either biochemical menopause as confirmed after chemotherapy, surgical or medicinally induced (GnRH analogues for the duration of the trial)

Exclusion criteria

Exclusion Criteria:

  • Not willing to abstain from vaginal intercourse for 1 week following laser therapy
  • Use of non-hormonal vaginal preparations within the last 6 weeks before inclusion
  • Use of hormonal therapy within 6 months prior to inclusion (systemic or local)
  • Acute urinary or genital tract infections
  • A history of genital fistula, a thin rectovaginal septum as determined by the investigator, or history of fourth degree laceration
  • Prolapse ≥ grade 2 according to the Pelvic Organ Prolapse Quantification System
  • Previous vaginal mesh implantation
  • Abnormal result in the last cervical smear (maximum 36 month before enrollment)
  • Active cancer treatment (radiotherapy or chemotherapy) ongoing or planned prior to the measurement of the primary outcome (6 months after inclusion, 3 months after last laser)
  • Vaginal stenosis that does not allow the placement of the laser probe
  • Any condition that could interfere with study compliance
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
162 participants (estimated)

Study arms

  • Active comparator
    Mona Lisa Touch CO2 laser

    1. Power: 30 W. 2. Dwell time: 1000 μs. 3. Spacing: 1000 μm. 4. Depth: SmartStack parameter from 1 to 3 depending on the treatment status. 5. D-pulse mode. 6. At the introitus the power will be reduced to 24 W

    Device: intravaginal laser

  • Active comparator
    Fotona Smooth erbium:YAG laser

    1. Phase I (vaginal) Renovalase™ mode with (a) fluence of 5,5J/cm2, (b) SMOOTHTM mode frequency 1.6 Hz, and (c) spot size 7 mm. 2. Phase II (vestibulum and introitus) Renovalase™ mode with (a) fluence 10 J/cm2, (b) SMOOTHTM mode frequency 1.6Hz, and (c) spot size 7 mm.

    Device: intravaginal laser

  • Sham comparator
    sham treatment

    1. The blocking device is inserted over the laser outlet before attaching the application speculum. With this device the laser beam is blocked entirely. 2. Phase I (vaginal) Renovalase™ mode with (a) fluence of 5,5J/cm2, (b) SMOOTHTM mode frequency 1.6 Hz, and (c) spot size 7 mm. 3. Phase II (vestibulum and introitus) Renovalase™ mode with (a) fluence 1,5 J/cm2, (b) SMOOTHTM mode frequency 1.6Hz, and (c) spot size 7 mm.

    Device: intravaginal laser

Interventions

  • Deviceintravaginal laser

    application of intravaginal laser

06

What researchers measure

Primary outcomes

  1. change in severity dryness as most bothersome symptom (MBS) of GSM at 3 months after the end of treatment

    scored on a 10 cm VAS

    Time frame: at 3 months after the end of treatment

Secondary outcomes

  1. Patient reported effect of laser on other GSM symptoms

    scored on a 10 cm VAS

    Time frame: at 3 months after the end of treatment

  2. Female Sexual Function Index (FSFI)

    measured with FSFI questionnaire. The cut-off score of \>26,55 will be used to discriminate between women with impaired and unimpaired sexual functioning

    Time frame: at 3 months after the end of treatment

  3. Urinary Distress Index (UDI-6)

    Measured with UDI-6 questionnaire

    Time frame: at 3 months after the end of treatment

  4. The degree of discomfort of the treatment procedure by the participant

    scored on a 10 cm VAS

    Time frame: at the end of the each treatment-visit

  5. The longevity of the effect

    Determined by questioning the need the participant feels for repeat treatment, and its nature (repeat laser or alternatives) until two years after the end of treatment.

    Time frame: at 24 months after the end of treatment

  6. Vaginal pH

    Measured with a pH indicator strip (range 3.6-6.1) and is sampled from the lateral vaginal wall in the lower third of the vagina

    Time frame: at 3 months after the end of treatment

  7. Vaginal Health Index Score (VHIS)

    Scoring of vaginal moisture, vaginal fluid volume, vaginal elasticity, vaginal pH, and vaginal epithelial integrity on a scale of 1 (poorest) to 5 (best) according to the methods of Robert Wood Johnson Medical School. The lower the score, the greater the atrophy. Vaginal moisture is an assessment of the appearance and spread or consistency of the secretions which coat the vagina. Vaginal elasticity is a measure of the ability of the vaginal tissue to stretch from the examiner's finger. Vaginal epithelial integrity takes into account color, thickness, and ability of the tissue to resist breaking secondary to touch.

    Time frame: at 3 months after the end of treatment

  8. Vaginal Maturation Value (VMV)

    A vaginal smear will be obtained from the lateral vaginal wall using a spatula and will be stained according to the Papanicolaou technique. The Vaginal Maturation Index (VMI) is evaluated by defining the proportion of superficial, intermediate, and parabasal epithelial cells on the smear. To combine this information into a single score for quantifying estrogenization, the VMV was calculated. It is based on weighted proportions of cell types from the VMI and calculated using Meisels' formula: the percentage of superficial cells (S) plus 0.5 times the percentage of intermediate cells (I) coded from the cytology sample \[MV= %S + (0.5 × % I)

    Time frame: at 3 months after the end of treatment

  9. Description of adverse events

    Adverse events are questioned at each visit following an intravaginal treatment.

    Time frame: until 1 month after the last treatment visit

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2024, 24 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 24 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2023
First posted
Feb 6, 2023
StartActual
Dec 27, 2022
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2025
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05713435
Responsible party
Sponsor
First posted
Feb 6, 2023
Start date
Dec 27, 2022
Primary completion
Dec 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jul 1, 2024

Study contacts

Susanne Housmans, MD
Contact
susanne.housmans@uzleuven.be
+3216332211
Jan Deprest, PhD
Contact
jan.deprest@uzleuven.be
+3216332211
Susanne Housmans, MD
principal investigator · UZ Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion